相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population >= 75 years: a pooled analysis from a database of clinical trials
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2011)
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
B. Ahren et al.
DIABETES OBESITY & METABOLISM (2011)
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial
V. Lukashevich et al.
DIABETES OBESITY & METABOLISM (2011)
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences
Roberta Baetta et al.
DRUGS (2011)
Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes
D. Serra et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes
Y.-L. He et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study
Y. Iwamoto et al.
DIABETES OBESITY & METABOLISM (2010)
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
D. R. Matthews et al.
DIABETES OBESITY & METABOLISM (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients
G. Derosa et al.
HORMONE AND METABOLIC RESEARCH (2010)
Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations
Raffaele Marfella et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2010)
Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes
Yan-Ling He et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Disposition of Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Rats and Dogs
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
Bo Ahren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes
David A. D'Alessio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
Pei Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
Yan-Ling He et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
C. Pan et al.
DIABETIC MEDICINE (2008)
Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2008)
Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia
Andrea Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
Koichiro Azuma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects
Surya P. Ayalasomayajula et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Gangadhar Sunkara et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers
Yon-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
Y.-L. He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Adrian Vella et al.
DIABETES (2007)
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
Yan-Ling He et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
F. Xavier Pi-Sunyer et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
Bogdan Balas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2007)
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2007)
Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
S. Dejager et al.
HORMONE AND METABOLIC RESEARCH (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
Emanuele Bosi et al.
DIABETES CARE (2007)
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
Yan-Ling He et al.
CLINICAL PHARMACOKINETICS (2007)
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
Yan-Ling He et al.
CLINICAL PHARMACOKINETICS (2007)
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
Pertti J. Neuvonen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro:: Potential for interactions with CYP2C8 inhibitors
Tiina Jaakkola et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
R. E. Pratley et al.
HORMONE AND METABOLIC RESEARCH (2006)
Contemporary use of digoxin in the management of cardiovascular disorders
Mihai Gheorghiade et al.
CIRCULATION (2006)
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials
NB Mistry et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Diabetes mellitus and atrial fibrillation: Perspectives on epidemiological and pathophysiological links
GYH Lip et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease
MR Movahed et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
S Ristic et al.
DIABETES OBESITY & METABOLISM (2005)
Patterns of antihypertensive therapy among patients with diabetes
ML Johnson et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
What do we know about the secretion and degradation of incretin hormones?
CF Deacon
REGULATORY PEPTIDES (2005)
Comparative pharmacokinetics of vitamin K antagonists - Warfarin, phenprocoumon and acenocoumarol
M Ufer
CLINICAL PHARMACOKINETICS (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community
CJ Östgren et al.
DIABETES OBESITY & METABOLISM (2004)
Therapeutic strategies based on glucagon-like peptide 1
CF Deacon
DIABETES (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes
MA Nauck et al.
DIABETES (2004)
Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
JJ Meier et al.
DIABETES (2004)
The role of sulphonylureas in the management of type 2 diabetes mellitus
M Rendell
DRUGS (2004)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
GIP a potential therapeutic agent?
JJ Meier et al.
HORMONE AND METABOLIC RESEARCH (2004)
Circulation and degradation of GIP and GLP-1
CF Deacon
HORMONE AND METABOLIC RESEARCH (2004)
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
T Prueksaritanont et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
JJ Meier et al.
DIABETOLOGIA (2003)
Altered homeostatic adaptation of first- and second-phase β-cell secretion in the offspring of patients with type 2 diabetes -: Studies with a minimal model to assess β-cell function
RC Bonadonna et al.
DIABETES (2003)
Meal and oral glucose tests for assessment of β-cell function:: modeling analysis in normal subjects
A Mari et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
JJ Holst
DIABETES-METABOLISM RESEARCH AND REVIEWS (2002)
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes
B Ahrén et al.
DIABETES CARE (2002)
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
J Kirchheiner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
MA Nauck et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans
J Schirra et al.
GUT (2002)
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
D Williams et al.
CLINICAL PHARMACOKINETICS (2002)
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Diabetes, hypertension, and cardiovascular disease - An update
JR Sowers et al.
HYPERTENSION (2001)
Pharmacogenetics of warfarin elimination and its clinical implications
H Takahashi et al.
CLINICAL PHARMACOKINETICS (2001)
分享论文
